The global market for prefilled syringes is expanding, driven by the rising prevalence of chronic illnesses, greater use of biologics and biosimilars, and a growing trend toward self-injection.

FDA approved Vyvgart Hytrulo prefilled syringe for gMG and CIDP self-injection in 20–30 seconds. Human factor studies showed patients and caregivers safely administered the new formulation.

The global market for prefilled syringes is expanding, driven by the rising prevalence of chronic illnesses, greater use of biologics and biosimilars, and a growing trend toward self-injection.

The U.S. Food and Drug Administration (FDA) on Thursday approved a new option for patients to self-inject Argenx SE’s (NASDAQ:ARGX) Vyvgart Hytrulo with a prefilled syringe (efgartigimod alfa ...

The U.S. Food and Drug Administration (FDA) on Thursday approved a new option for patients to self-inject Argenx SE’s (NASDAQ:ARGX) Vyvgart Hytrulo with a prefilled syringe (efgartigimod alfa and ...

“We understand patients experience MG and CIDP in different ways, and our prefilled syringe is an important innovation that provides patients with more freedom and flexibility to self-administer ...

Halozyme Therapeutics, Inc. (Halozyme) announced that argenx has received US Food and Drug Administration (FDA) approval of Vyvgart Hytrulo prefilled syringe for self-injection (efgartigimod alfa and ...

The US Food and Drug Administration (FDA) has approved a prefilled syringe for self-injection of efgartigimod alfa and hyaluronidase-qvfc (Vyvgart Hytrulo, argenx) in the treatment of adults with ...

The U.S. regulator has signed off on argenx’s prefilled syringe (PFS) version of Vyvgart Hytrulo, which allows patients to self-inject at home as opposed to undergoing infusions or making weekly ...

(RTTNews) - Halozyme Therapeutics Inc. (HALO) announced that argenx has received U.S. Food and Drug Administration approval of VYVGART Hytrulo prefilled syringe for self-injection (efgartigimod ...

The Food and Drug Administration (FDA) has approved a prefilled syringe formulation of Vyvgart ® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) that allows patients to self-inject the medication.

VYVGART ® Hytrulo prefilled syringe for self-injection is approved as a 20-to-30-second subcutaneous injection administered by a patient, caregiver, or healthcare professional. Patients are able ...